However, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) proved that reducing hs-CRP level through the IL-1β and downstream IL-6-receptor signaling pathway by canakinumab (a monoclonal antibody targeting IL-1β) without reducing LDL-C level significantly lowered the incidence of recurrent cardiovascular events38. This evidence concerns the gene IL1B and deep vein thrombosis.